Uses of Soravir

Soravir is used in combination with other medicines to treat chronic hepatitis C in adults. Soravir has the main ingredient Sofosbuvir. Let's find out more details about the uses, usage and notes of Soravir drug line through the article below.

What is Soravir? Soravir drug belongs to the group of anti-parasitic, anti-infective, anti-viral, anti-fungal drugs... Soravir is made in the form of film-coated tablets packed in boxes of 4 blisters x 7 tablets, boxes of 3 blisters x 10 tablets.
Soravir medicine has the main ingredient Sofosbuvir 400mg and other excipients, just enough for 1 tablet.
Soravir of Pymepharco Joint Stock Company, is used in the combined treatment of liver diseases caused by viruses, especially chronic hepatitis C.

What does Soravir do? Soravir has the following main effects:
Inhibiting the replication of chronic hepatitis C virus in the patient's body. Strengthen the immunity of sick people to avoid other viral infections and bacterial infections. Gradually restore liver function and liver cells. The most effective treatment effect when used in combination with other antiviral drugs such as Ledipasvir, Ribavirin, ...

3.1. How to take Soravir is taken orally, the patient should take it with meals.
Take Soravir tablets whole with an appropriate amount of water, do not chew or crush.
3.1. Dosage Dose of Soravir according to strict instructions from the treating doctor. The recommended dose of Soravir is given as follows:
Take 1 Soravir tablet / time / day. Used in combination with other drugs, Soravir should not be used as monotherapy. Take an additional dose of Sofosbuvir if the patient vomits within 2 hours of taking it. Combination therapy:
Patients with CHC with genotypes 1, 4, 5, 6: Take 400mg Sofosbuvir, Ribavirin and Peginterferon alfa for 12 weeks or 400mg Sofosbuvir and Ribavirin for 24 weeks. Patients with CHC with genotype 2: Take 400mg of Sofosbuvir and Ribavirin for 12 weeks. Patients with CHC with genotype 3: Take 400mg of Sofosbuvir, Ribavirin and Peginterferon alfa for 12 weeks or 400mg of Sofosbuvir and Ribavirin for 24 weeks. Patients with CHC awaiting liver transplant: Take 400mg of Sofosbuvir and Ribavirin until liver transplantation. Special populations:
Elderly: No dose adjustment of Sofosbuvir is required. Renal impairment: No dose adjustment of Sofosbuvir is required in patients with mild and moderate renal impairment. A safe dose of Sofosbuvir in patients with severe renal impairment or end-stage renal disease requiring hemodialysis has not been established. Hepatic impairment: No dose adjustment of Sofosbuvir is required in patients with mild, moderate or severe hepatic impairment. Safe and effective doses of Sofosbuvir in patients with decompensated cirrhosis have not been established. Patients awaiting liver transplantation: The duration of Sofosbuvir is assessed based on potential benefits and risks. Liver transplant recipients: It is recommended that Soravir and Ribavirin be used in combination for 24 weeks. Take the starting dose of Ribavirin 400mg in 2 divided doses with food. The dose may be increased to 1000 - 1200 mg of Ribavirin/day if Ribavirin is well tolerated. Reduce dose of Ribavirin as clinically indicated based on hemoglobin level if not well tolerated. Children and adolescents under 18 years of age: The safety and effectiveness of Soravir have not been established.

Soravir should not be used in the following cases:
Patients with hypersensitivity to Sofosbuvir or any of the excipients of the drug. Do not combine sofosbuvir is used in combination with ribavirin or peginterferon alfa/ribavirin. Pregnant women, preparing to become pregnant because there is a risk of causing deformity or death of the fetus. Breastfeeding. Severe heart disease, ischemic heart disease, uncontrolled heart disease within the past 6 months. Patients with chronic renal failure or with creatinine clearance <50ml/min or patients on dialysis. Severe liver failure, decompensated cirrhosis. Anemia, sickle cell disease, Mediterranean anemia. Have a history of, or are currently suffering from, a mental illness, severe mental disorder, major depression, suicidal thoughts or attempted suicide. History of or current autoimmune hepatitis. The patient is hypersensitive to benzylic alcohol, eggs or neomycin, to rat proteins.

Here are some of the reported Soravir drug interactions:
Amiodaron. Modafinil may cause a decrease in Sofosbuvir levels. Phenytoin, Phenobarbital, Rifabutin, Rifapentin, Carbamazepine, H. perforatum, Rifampicin can significantly reduce the plasma concentration of Sofosbuvir. To ensure safety and effectiveness during the use of Soravir, patients should inform their doctor of all drugs or supplements they are taking and any medical conditions they are suffering from so that they can guide the appropriate use of Soravir. fit.

During the treatment of Soravir, patients may experience some unwanted side effects such as:
Fatigue, headache Nausea, diarrhea Itching skin Difficulty sleeping or body discomfort may occur. out. Tell your doctor right away if you have any serious Soravir side effects, including signs of a low red blood cell count such as: unusual tiredness, rapid breathing, trouble breathing, fast heart rate. pale skin.

Do not take Soravir with other products containing sofosbuvir. Sofosbuvir should be used with caution in patients with kidney disease, liver problems, or hepatitis B. In the case of pregnant women taking sofosbuvir, there are limited data. Animal studies with sofosbuvir have not shown a direct effect. directly or indirectly related to reproductive toxicity. The highest dose of sofosbuvir tested had no effect on rat and rabbit fetal development. Therefore, as a precaution, the use of sofosbuvir should be avoided during pregnancy. Lactation: It is not known whether sofosbuvir is excreted in human milk. It was reported that metabolites of Soravir appeared in animal milk. Therefore, to avoid risks to the nursing infant, Soravir should not be used while breastfeeding. Soravir has the potential to cause dizziness, decreased concentration, fatigue, and decreased vision. Use Soravir with caution when driving and operating machinery. Soravir is available by prescription and over-the-counter. If drugs used in combination with Soravir are permanently discontinued, the patient should also stop taking Soravir. Soravir can cause bradycardia and severe heart block. Soravir should be considered in patients previously treated for HCV genotypes 1, 4, 5 and 6. Clinical data supporting the use of Soravir in patients with HCV genotypes 5 and 6 are limited. limit. Non-interferon regimens for patients infected with HCV genotypes 1, 4, 5 and 6 with Sofosbuvir have not been studied. Soravir should only be combined with direct antiviral agents if the benefits outweigh the risks. When using Ribavirin in combination with Soravir, women of childbearing potential or their partners must use effective contraception during and after treatment. Co-administration of Soravir with inducers of moderate intestinal P-gp (Oxcarbazepine, Modafinil, ...) may reduce plasma concentrations of Sofosbuvir. Soravir is used in combination with other medicines to treat chronic hepatitis C in adults. Soravir has the main ingredient Sofosbuvir. To ensure the effectiveness of treatment and avoid unwanted side effects, patients need to strictly follow the instructions of the doctor, professional pharmacist.
Follow Vinmec International General Hospital website to get more health, nutrition and beauty information to protect the health of yourself and your loved ones in your family.